Matthias Wirth studied biology in Düsseldorf and received his Master's degree in 2008. He then switched to biomedical research and studied MYC-related proliferation and apoptosis mechanisms in pancreatic cancer at the TU Munich for his doctoral thesis.
He continued his studies there as a postdoctoral candidate and then obtained a position as group leader in Düsseldorf, and subsequently a position as group leader and PI at the Charité Berlin.
His research focuses on the development of new therapeutic options for MYC-driven cancers.